Adding Elraglusib to Chemotherapy Extends Survival in Metastatic PDAC Adding elraglusib to chemotherapy significantly increases overall survival in patients with previously untreated metastatic PDAC.

Adding elraglusib, a novel small-molecule inhibitor, to chemotherapy significantly increases OS in patients with previously untreated metastatic #PDAC. Presented at @ascocancer.bsky.social conference #GI26.

https://bit.ly/3ZFQztG

#pancsm

Excellent work summarizing #pancsm studies @graokane.bsky.social #GIonc @oncoalert.bsky.social #GIonc

NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer #pancsm #oncology www.onclive.com/view/nalirif...

Cyst Wall Thickening Best Predicts BD-IPMN Progression to Pancreatic Cancer - Oncology Nurse Advisor Researchers examined the long-term natural history of branch-duct intraductal papillary mucinous neoplasms and sought to identify clinical and radiologic factors linked to developing pancreatic cancer during surveillance.

At 10 years after detection of branch-duct BD-IPMN, the cumulative incidence of IPMN-derived invasive #carcinoma and de novo PDAC was 5.5%. Published in @gastroadvisor.bsky.social.

https://bit.ly/3NjBz1Z

#pancsm #pancreaticcancer

Pancreatic Cancer Therapy: What Comes Next? Dr Emil Lou breaks down what’s changing in pancreatic cancer care, including neoadjuvant chemotherapy, genomic testing, and why progress remains incremental.

Dr Emil Lou, medical oncologist & specialist in gastrointestinal cancers at the University of Minnesota talks about all things, updates, & advances in #pancreaticcancer , including #BRCA & #PARP therapies @medscape.com

#hereditarycancer #pancchat #medsky #genetics #pancsm

WVU Medicine Experts First in Nation to Use Innovative Endoscopy-Guided Microwave Therapy to Treat Pancreatic Lesions
#pancsm #oncology
www.onclive.com/view/wvu-med...

Penpulimab-Based Quadruplet Yields Efficacy Improvements in Metastatic Pancreatic Cancer | OncLive Penipulimab plus anlotinib and chemotherapy showed improved efficacy compared with chemotherapy alone in treatment-naïve metastatic pancreatic cancer.

Penpulimab-Based Quadruplet Yields Efficacy Improvements in Metastatic Pancreatic Cancer
#pancsm #oncology #GI26
www.onclive.com/view/penpuli...

Happening now at #GI26: “Rapid Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract” chaired by Dr. Arndt Vogel. #pancsm #hpbcsm

meetings.asco.org/meetings/202...

Learning about evolving strategies and “Multidisciplinary Approaches to Borderline Resectable and Locally Advanced Pancreatic Cancer” right now at #GI26, including surgical techniques, precision radiation, and more: meetings.asco.org/meetings/202...

#pancsm

Getting the latest research into cancers of the pancreas, small bowel & hepatobiliary tract at #GI26 Oral Abstract Session B chaired by Dr Neehar Parikh & Dr Myriam Chalabi following a welcome & Meetings App poll feature warm-up from Dr David Wang. #pancsm #hpbcsm meetings.asco.org/meetings/202...

Just activated!
#NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice SOC w/wo panitumumab. #pancsm
PI: Rachael A. Safyan, MD @fredhutch.org
swog.org/clinical-tri...

Asynchronous Electronic Consent for Research Acceptable Among Patients With Cancer - Oncology Nurse Advisor Researchers reported on patient acceptance of an e-consent tool for asynchronous delivery of study information and for receiving consent from patients.

The use of an asynchronous e-consent process for prospectively evaluating circulating tumor DNA in patients with colorectal or #pancreaticCancer appeared acceptable among patients in a recent study.

https://bit.ly/4oCHvjC

#pancsm #gicsm

Mild Dilatation of the Main Pancreatic Duct Is a Risk Factor for Progression to Pancreatic Cancer in High-Risk Individuals Mild dilatation of the main pancreatic duct (MPD) can be an early indicator of an obstructing mass, but its clinical significance in asymptomatic high-risk individuals (HRIs) undergoing surveillance h...

Mild Dilatation of the Main Pancreatic Duct Is a Risk Factor for Progression to #PancreaticCancer in High-Risk Individuals.

#cancerresearch #medsky #pancsm

Excess Weight Linked to Increased Risk for Early-Onset Pancreatic Cancer In this study, researchers evaluated the dose-response relationship between body mass index and the risk of developing pancreatic cancer by the age of 50 years.

#Overweight and obesity are both associated with a greater risk of developing #pancreaticcancer by the age of 50 years.

https://bit.ly/4pAzsVm

#pancsm

A 13-year survivor of Stage 4 #pancreaticcancer, Steve Merlin now travels the world & mentors other patients with the same diagnosis. His mother had died of #breastcancer, & he inherited her faulty #BRCA gene.

#hereditarycancer #genetics #PARP #patientexperience #pancsm #medsky #cancerresearch

Cristina Ferrone, MD, of Massachusetts General Hospital leads Alliance A021806 studying whether chemotherapy before and after surgery is better than just after surgery for pancreas cancer. Learn more: https://bit.ly/Alliance-A021806 #NCI #NCTN #pcam #PanCancer #PancSM #PancreaticCancerAwarenessMonth

Personalized, Patient-Centered Strategies Shape the Evolving Management of Metastatic Pancreatic Cancer | OncLive Efrat Dotan, MD, discusses patient factors to consider during treatment planning for metastatic pancreatic cancer.

Personalized, Patient-Centered Strategies Shape the Evolving Management of Metastatic Pancreatic Cancer #pancsm #oncology www.onclive.com/view/persona...

Long preoperative chemo elicited more pathologic complete responses than short preoperative chemo in PDAC, but no difference in EFS was seen. Presented at #ESMO25 by Dr Michele Reni of San Raffaele Scientific Institute. #gicsm #pancsm #esmo2025

shorturl.at/cPimQ

Hair Straightener, Chemical Relaxer Use Linked to Certain Non-Reproductive Cancers The use of hair straighteners and chemical relaxers may be associated with a higher incidence of pancreatic cancer, thyroid cancer, and non-Hodgkin's lymphoma, according to a study.

The use of hair straighteners and chemical relaxers may be associated with an increased risk of certain non-reproductive cancers, including pancreatic cancer, thyroid #cancer, and non-Hodgkin’s lymphoma.

https://bit.ly/3KPV54O

#pancsm #lymsm

You may be eligible to participate in a #PancreaticCancer study, EA2192/APOLLO, for patients with #PancreaticCancer that has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation. Learn more: bit.ly/apollo-trial #pancsm

It's time for the #FiveUnder5 🕒. Check out the top #oncology videos of the week: www.onclive.com/view/five-un...

@danafarber.bsky.social @harvardmed.bsky.social @mountsinainyc.bsky.social #bcsm #pancsm #mmsm #medtwitter

First-Line Atebimetinib Plus mGnP Yields High 9-Month OS Rate in Pancreatic Cancer | OncLive Atebimetinib plus modified gemcitabine/nab-paclitaxel continued to elicit high OS rates in patients with treatment-naive pancreatic cancer.

First-Line Atebimetinib Plus mGnP Yields High 9-Month OS Rate in Pancreatic Cancer @cityofhope.bsky.social #pancsm #oncology
www.onclive.com/view/first-l...

Roswell Park Study Reveals New Clues to Pancreatic Cancer Spread—and a Possible Way to Stop It Findings suggest that treatment with an FGFR4 inhibitor can disrupt tumor spread in pancreatic cancer.

Roswell Park Study Reveals New Clues to Pancreatic Cancer Spread—and a Possible Way to Stop It
@roswellpark.bsky.social #PancreaticCancer #pancsm
www.onclive.com/view/roswell...

Fc-Enhanced Agents May Expand Anti–CTLA-4 Approaches in GI Cancers To extend the benefits of CTLA-4 inhibitors to poorly immunogenic tumors like HCC and CRC, investigators are developing Fc-enhanced CTLA-4 inhibitors.

Fc-Enhanced Agents May Expand Anti–CTLA-4 Approaches in GI Cancers @harvardmed.bsky.social @bidmc-cancercenter.bsky.social #crcsm #pancsm #oncology
www.onclive.com/view/fc-enha...

Novocure Files Premarket Approval Application to FDA for Tumor Treating Fields in Locally Advanced Pancreatic Cancer The FDA has received a premarket approval application for TTFields in locally advanced pancreatic cancer.

Novocure Files Premarket Approval Application to FDA for Tumor Treating Fields in Locally Advanced Pancreatic Cancer
#PancreaticCancer #pancsm @fda.gov
www.onclive.com/view/novocur...

Disparities in Guideline-Concordant Care for Pancreatic Cancer Patient comorbidities, dual-eligibility status, and area-level poverty were the strongest contributing factors to the disparities observed between Black and White patients, researchers found.

Racial and ethnic disparities in receipt of guideline-concordant care for pancreatic cancer differ by disease stage, research suggests. shorturl.at/AwE63 #pancsm #gicsm

Gut Microbiome Linked to Treatment Response in Pancreatic Cancer The composition of the gut microbiome appears to be associated with treatment response in patients with pancreatic cancer, research suggests.

The composition of the gut microbiome appears to be associated with treatment response in pancreatic cancer, and adding immunotherapy to treatment may have a beneficial effect on the microbiome, according to research presented at #ESMOGI25. shorturl.at/T3y4N #gicsm #pancsm

From Caregiver to Nurse, Overnight When a loved one is being treated for pancreatic cancer, caregivers become at-home nurses. Marci Andrejko provides some best practices.

When a loved one is being treated for pancreatic cancer, caregivers become at-home nurses. Marci Andrejko provides some best practices. buff.ly/nfFxZls #OncoSky #PanCSM

Using AI—Dos and Dont’s Artificial intelligence can have many benefits for patients and caregivers, organizing complex information, but it must be used properly.

Artificial intelligence can offer numerous benefits for patients and caregivers by organizing complex information, but it must be used properly. buff.ly/iyRFrM5 #AI #PanCSM

Certepetide Plus Chemotherapy Shows ORR, PFS Benefits Over Placebo in Metastatic PDAC Certepetide plus gemcitabine and nab-paclitaxel was safe and effective in patients with untreated metastatic pancreatic ductal adenocarcinoma.

Certepetide Plus Chemotherapy Shows ORR, PFS Benefits Over Placebo in Metastatic PDAC @myesmo.bsky.social #ESMOGI25 #pancsm #oncology
www.onclive.com/view/certepe...